1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2024, Issue 3
  5. Article
Volume 2024, Issue 3
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Background: Gastric cancer is one of the leading causes of cancer-related deaths worldwide. Despite advances in treatment options, the overall prognosis for advanced gastric cancer remains poor. Immunotherapy has revolutionized the field of cancer treatment by harnessing the patient’s immune system to target and destroy cancer cells. Two important immune checkpoint inhibitors that have shown promise in various malignancies, including gastric cancer, are program death-1 and cytotoxic T lymphocyte-4 inhibitors.

Aims: To assess and analyze the occurrence of adverse events associated with program death-1 and cytotoxic T lymphocyte antigen-4 in patients diagnosed with advanced gastric cancer.

Methods: Relevant studies were searched in reputable databases such as PubMed, Embase, Google Scholar, and the Cochrane Library from October 6, 2017, to February 3, 2022. Studies were analyzed with Review Manager 5.4. PROSPERO: CRD42023479662.

Results: Of the 500 studies retrieved, nine randomized control trials involving 5,185 patients were included in the meta-analysis comparing TRAEs in advanced gastric cancer patients after immune checkpoint inhibitor monotherapy and combined immune checkpoint inhibitors treatment. There was a lower risk of any grade of treatment-related adverse events with program death -1 than in the control arm (76.5% vs. 79%, P = 0.02). Program death-1 observed a lesser risk of grade 3-4 treatment-related adverse events as compared to the control for nausea (0.3% vs. 3%, P = 0.007) and fatigue (1% vs. 2.7%, P = 0.006). Program death-1 monotherapy also saw a decrease in the incidence of common treatment-related adverse events such as diarrhea (9.6% vs. 16%, P < 0.00001), nausea (6.8% vs. 20.6%, P < 0.00001) and fatigue (11% vs. 15.9%, P = 0.001). However, pruritus occurrence increased (3.8% vs. 9%, P < 0.001) after program death-1 compared to control.

Conclusions: Patients with advanced gastric cancer endured program death-1 treatment effectively. Nonetheless, the combination of program death-1 and cytotoxic T lymphocyte-4 results in a greater occurrence of treatment-related adverse events.

© 2024 Theophilus, Wang, Da, Xu, Li, Chen, et al., Licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2024.31
2024-08-27
2025-01-15
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2024/3/qmj.2024.31.html?itemId=/content/journals/10.5339/qmj.2024.31&mimeType=html&fmt=ahah

References

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021Jan; 71:(1):7-33. doi: 10.3322/caac.21654
     [Google Scholar]
  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021May; 71:(3):209-249. doi: 10.3322/caac.21660
     [Google Scholar]
  3. Yoon J, Kim TY, Oh DY. Recent Progress in Immunotherapy for Gastric Cancer. J Gastric Cancer. 2023Jan; 23:(1):207-223. doi: 10.5230/jgc.2023.23.e10
     [Google Scholar]
  4. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al.. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013Oct; 24:Suppl 6:vi57-63. doi: 10.1093/annonc/mdt344
     [Google Scholar]
  5. Chang JS, Kuo SH, Chu PY, Shan YS, Tsai CR, Tsai HJ, et al.. The Epidemiology of Gastric Cancers in the Era of Helicobacter pylori Eradication: A Nationwide Cancer Registry-Based Study in Taiwan. Cancer Epidemiol Biomarkers Prev. 2019Oct; 28:(10):1694-1703. doi: 10.1158/1055-9965.EPI-19-0355
     [Google Scholar]
  6. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14:(1):26-38. doi: 10.5114/pg.2018.80001
     [Google Scholar]
  7. Lee HS, Kim WH, Kwak Y, Koh J, Bae JM, Kim KM, et al.. Molecular Testing for Gastrointestinal Cancer. J Pathol Transl Med. 2017Mar; 51:(2):103-121. doi: 10.4132/jptm.2017.01.24
     [Google Scholar]
  8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006Jul6; 355:(1):11-20. doi: 10.1056/NEJMoa055531
     [Google Scholar]
  9. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010Aug28; 376:(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X
     [Google Scholar]
  10. Jin X, Liu Z, Yang D, Yin K, Chang X. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer. Front Immunol. 2022Jul1; 13:948647. doi: 10.3389/fimmu.2022.948647
     [Google Scholar]
  11. Bonotto M, Garattini SK, Basile D, Ongaro E, Fanotto V, Cattaneo M, et al.. Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Rev Clin Pharmacol. 2017Jun; 10:(6):609-619. doi: 10.1080/17512433.2017.1313113
     [Google Scholar]
  12. Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel). 2022Feb18; 14:(4):1054. doi: 10.3390/cancers14041054
     [Google Scholar]
  13. Khan S, Siddique R, Bai Q, Shabana, Liu Y, Xue M, et al.. Coronaviruses disease 2019 (COVID-19): Causative agent, mental health concerns, and potential management options. J Infect Public Health. 2020Dec; 13:(12):1840-1844. doi: 10.1016/j.jiph.2020.07.010
     [Google Scholar]
  14. Khan S, Liu Y, Siddique R, Nabi G, Xue M, Hou H. Impact of chronically alternating light-dark cycles on circadian clock mediated expression of cancer (glioma)-related genes in the brain. Int J Biol Sci. 2019Jul20; 15:(9):1816-1834. doi: 10.7150/ijbs.35520
     [Google Scholar]
  15. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012Mar22; 12:(4):252-64. doi: 10.1038/nrc3239
     [Google Scholar]
  16. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al.. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009Aug20; 114:(8):1537-44. doi: 10.1182/blood-2008-12-195792
     [Google Scholar]
  17. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002Nov; 3:(11):991-8. doi: 10.1038/ni1102-991
     [Google Scholar]
  18. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002Sep17; 99:(19):12293-7. doi: 10.1073/pnas.192461099
     [Google Scholar]
  19. Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al.. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019Mar1; 17:(3):255-289doi: 10.6004/jnccn.2019.0013
     [Google Scholar]
  20. Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018Mar30; 10:1758835918764628. doi: 10.1177/1758835918764628
     [Google Scholar]
  21. Zhou C, Zhang J. Immunotherapy-based combination strategies for treatment of gastrointestinal cancers: current status and future prospects. Front Med. 2019Feb; 13:(1):12-23. doi: 10.1007/s11684-019-0685-9
     [Google Scholar]
  22. Kim BJ, Jang HJ, Kim HS, Kim JH. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J Cancer. 2017May19; 8:(8):1460-1465doi: 10.7150/jca.18470
     [Google Scholar]
  23. Wang D, Lin J, Yang X, Long J, Bai Y, Yang X, et al.. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol. 2019Apr24; 12:(1):42doi: 10.1186/s13045-019-0730-9
     [Google Scholar]
  24. Park R, Lopes L, Cristancho CR, Riano IM, Saeed A. Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. Front Oncol. 2020Mar17; 10:258. doi: 10.3389/fonc.2020.00258
     [Google Scholar]
  25. Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al.. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunol Res. 2018Sep; 6:(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755
     [Google Scholar]
  26. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy. 2015; 7:(11):1213-27. doi: 10.2217/imt.15.87
     [Google Scholar]
  27. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021Mar29; 372:n71. doi: 10.1136/bmj.n71
     [Google Scholar]
  28. G G. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3E: McGraw-Hill Education / Medical;. 2014.
    [Google Scholar]
  29. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009Jul21; 6:(7):e1000097doi: 10.1371/journal.pmed.1000097
     [Google Scholar]
  30. Deeks J, Higgins J, Altman D. Chapter 9: Analyzing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions version. 2011; 5:(0)
     [Google Scholar]
  31. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al.. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017Dec2; 390:(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5
     [Google Scholar]
  32. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al.. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021Apr1; 384:(13):1191-1203. doi: 10.1056/NEJMoa2032125
     [Google Scholar]
  33. Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al.. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020May; 23:(3):510-519. doi: 10.1007/s10120-019-01034-7
     [Google Scholar]
  34. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al.. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020Oct1; 6:(10):1571-1580doi: 10.1001/jamaoncol.2020.3370
     [Google Scholar]
  35. Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al.. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022Mar; 603:(7903):942-948. doi: 10.1038/s41586-022-04508-4
     [Google Scholar]
  36. Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, et al.. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018Oct1; 29:(10):2052-2060. doi: 10.1093/annonc/mdy264
     [Google Scholar]
  37. Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al.. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer. 2022Jan; 25:(1):197-206. doi: 10.1007/s10120-021-01227-z
     [Google Scholar]
  38. Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al.. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022Feb3; 386:(5):449-462. doi: 10.1056/NEJMoa2111380
     [Google Scholar]
  39. Moehler M, Dvorkin M, Boku N, Özgüroğlu M, Ryu MH, Muntean AS, et al.. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021Mar20; 39:(9):966-977doi: 10.1200/JCO.20.00892
     [Google Scholar]
  40. Health UDo, Services H. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 4.0. 2009. 2014.
    [Google Scholar]
  41. Wang BC, Zhang ZJ, Fu C, Wang C. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2019Nov; 98:(47):e18054. doi: 10.1097/MD.0000000000018054
     [Google Scholar]
  42. Chen C, Zhang F, Zhou N, Gu YM, Zhang YT, He YD, et al.. Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology. 2019Mar5; 8:(5):e1581547doi: 10.1080/2162402X.2019.1581547
     [Google Scholar]
  43. Shaibu Z ZW, Chen Z-H, Twum Ampofo DD, Bayorbor L, Asamoa Agyapong K. Systematic Review and Meta-Analysis of PD-1 and CTLA-4 Bispecific Antibody in the Treatment of Gastric Cancer. Review. Clin Oncol. 2022;7.
    [Google Scholar]
  44. Abdel-Rahman O, Oweira H, Giryes A. Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. Expert Rev Anticancer Ther. 2018Dec; 18:(12):1231-1239. doi: 10.1080/14737140.2018.1528146
     [Google Scholar]
  45. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021Jan30; 397:(10272):375-386. doi: 10.1016/S0140-6736(20)32714-8
     [Google Scholar]
  46. Pan S, Li K, Huang B, Huang J, Xu H, Zhu Z. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials. Ann Transl Med. 2021Feb; 9:(4):290. doi: 10.21037/atm-20-6639
     [Google Scholar]
  47. Wei W, Luo Z, Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. Medicine (Baltimore). 2017Dec; 96:(48):e8931. doi: 10.1097/MD.0000000000008931
     [Google Scholar]
/content/journals/10.5339/qmj.2024.31
Loading
Exploring program death-1 and cytotoxic T lymphocyte antigen-4 safety in gastric cancer clinical trials: A meta-analysis
Qatar Medical Journal 2024, 31 (2024); https://doi.org/10.5339/qmj.2024.31
/content/journals/10.5339/qmj.2024.31
/content/journals/10.5339/qmj.2024.31
Loading

Data & Media loading...

  • Article Type: Review Article
Keyword(s): adverse effects, cytotoxic T lymphocyte-4 antigen, immune checkpoint inhibitors, meta-analysis, Program cell death-1 receptor and stomach neoplasm

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error